Research & Development

Louisiana Case Could End Nationwide Telehealth Abortion Access
Research & Development Louisiana Case Could End Nationwide Telehealth Abortion Access

While medication abortion is FDA-approved for use up to eleven weeks of pregnancy, a new legal effort argues that state-level bans are being undermined by mail-order access. This challenge, currently centered in Louisiana, targets the regulatory framework that allows physicians to prescribe

Can a New Gene Test Prevent Fatal Lamotrigine Reactions?
Research & Development Can a New Gene Test Prevent Fatal Lamotrigine Reactions?

Although lamotrigine is a staple treatment for bipolar disorder and epilepsy, it triggers a dangerous systemic immune response in approximately one out of every thousand patients. Known as Stevens-Johnson Syndrome, this reaction causes severe skin detachment and organ damage. For years, doctors

FDA Approves Etcamah for Resistant Metastatic Breast Cancer
Research & Development FDA Approves Etcamah for Resistant Metastatic Breast Cancer

In the United States, 300,000 new cases of breast cancer are diagnosed annually, many of which will eventually progress to a more resistant metastatic state. For patients facing these advanced stages, the traditional arsenal of chemotherapy and hormonal blockers often loses its efficacy over time,

Can CAR-T Overcome Safety Hurdles in Autoimmune Care?
Research & Development Can CAR-T Overcome Safety Hurdles in Autoimmune Care?

Novartis and Bristol Myers Squibb have inadvertently set a new precedent for transparency as they navigate the complex safety challenges of applying oncology tools to chronic autoimmune diseases. This strategic pivot reflects a broader industry realization that the risk-benefit calculus for

How Is AstraZeneca Redefining the Future of Oncology?
Research & Development How Is AstraZeneca Redefining the Future of Oncology?

The synthesis of combination therapies and early detection creates a feedback loop that amplifies the effectiveness of modern cancer treatment protocols. This paradigm shift means oncologists no longer view cancer as a static entity confined to a single organ like the lung or breast. Instead, they

Superluminal Medicines Raises $60M for Rare Obesity Drug
Research & Development Superluminal Medicines Raises $60M for Rare Obesity Drug

By targeting the MC4R receptor with a small-molecule approach, Superluminal Medicines seeks to provide relief for patients suffering from hyperphagia and rare metabolic defects. This ambitious goal is now backed by a significant $60 million Series A funding round led by RA Capital Management, with

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later